Management and Future Directions for APS

Moderator(s)

• 

  Vinicius Domingues, MD

  Florida State university

Speaker(s)

• 

  Maria Laura Bertolaccini, PhD

  King's College London
• TO

  Thomas Ortel

  Duke University Medical Center
• 

  Jason Knight, MD, PhD

  University of Michigan

This session will explore in depth multiple concepts in antiphospholipid syndrome (APS). Faculty will focus on novel antibodies that can be associated with APS and can likely predict future thrombotic episodes. The focus of the session will also include scientific evidence against the use of DOACs in APS, and faculty will reiterate the current standard of care. Lastly, potential new clinical criteria will be discussed, as well as the hope for clinical therapy in the future.

Learning Objectives:

• Review new antibodies for APS
• Discuss predictive tools for thrombosis in APS
• Explain the evidence against the use of DOACs in APS
• Review the current standard of care in APS
• Review potential new criteria and therapeutic opportunities for the new decade

Presentations:

• 3:00 PM – 3:15 PM ET

  Novel and Non-Criteria Antibodies for APS in 2020
  Maria Laura Bertolaccini, PhD – King's College London
• 3:15 PM – 3:30 PM ET

  Current Recommendations for Treatment of APS and Evidence Against the Use of DOACs
  Thomas Ortel – Duke University Medical Center
• 3:30 PM – 3:45 PM ET

  What to Expect from a New Decade for APS
  Jason Knight, MD, PhD – University of Michigan
• 3:45 PM – 4:00 PM ET

  Q&A